Hyqvia (Human Normal Immunoglobulin, Hyaluronidase (Human Recombinant))

Hyqvia is used in the management of primary immunodeficiency disorders, delivering immunoglobulin replacement to restore antibody levels.

• Primary Common Variable Immunodeficiency (CVID): reduces frequency and severity of infections by providing necessary IgG antibodies.
• X‑linked Agammaglobulinemia (XLA): supplies missing immunoglobulins to support immune function.
• Severe Combined Immunodeficiency (SCID) post‑hematopoietic stem cell transplant: aids immune reconstitution during recovery.

• Hyqvia combines human normal immunoglobulin with recombinant human hyaluronidase. The immunoglobulin component supplies a broad spectrum of IgG antibodies that replace the patient’s deficient antibodies, providing passive immunity. Hyaluronidase temporarily depolymerizes hyaluronan in the subcutaneous extracellular matrix, increasing tissue permeability and allowing a larger volume of immunoglobulin to be dispersed and absorbed rapidly after subcutaneous infusion.

Hyqvia may be associated with a range of adverse reactions following subcutaneous administration.

Common Side Effects

• Infusion site erythema or swelling: mild redness or puffiness at the injection site.
• Headache: transient pain in the head region.
• Nausea: mild to moderate feeling of queasiness.
• Fatigue: temporary tiredness or lack of energy.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Thromboembolic events: blood clots that may lead to vascular complications.
• Renal dysfunction: impaired kidney function, especially with high cumulative doses.
• Aseptic meningitis: inflammation of the meninges without infection.

Before initiating Hyqvia therapy, consider the following precautions to ensure safe and effective use.

• Assess immunoglobulin levels: confirm deficiency and need for replacement therapy.
• Monitor for infection risk: patients with active infections may require treatment postponement.
• Evaluate renal function: baseline and periodic kidney tests are recommended.
• Review vaccine schedule: live vaccines should be avoided during treatment.
• Consider anticoagulant therapy: monitor bleeding risk if patient is on anticoagulants.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hyqvia can interact with other medicines; awareness of major and moderate interactions helps manage patient safety.

Major Interactions (Avoid)

• Live attenuated vaccines: may cause uncontrolled infection due to altered immune response.
• High‑dose aspirin or NSAIDs: increase risk of bleeding when combined with hyaluronidase‑mediated tissue changes.
• Monoclonal antibodies targeting IgG: may reduce efficacy of immunoglobulin therapy.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): monitor INR as hyaluronidase may affect subcutaneous absorption.
• Renally cleared antibiotics (e.g., aminoglycosides): watch for additive renal toxicity.
• Inactivated vaccines: may have reduced immunogenicity; assess antibody response.
• Other immunoglobulin products: stagger administration to avoid overlapping infusion sites.